ABVC BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	0.72	1.39	6.57	5	0.16
Short-Term Investments	0.08	0.08	0.11	0	0
Cash & Cash Equivalents	0.8	1.47	6.67	5	0.16
Cash Growth	-45.75%	-78.01%	33.43%	3017.23%	-
Receivables	0.76	1.37	0.43	1	0.64
Inventory	0	0	0.03	0	0
Other Current Assets	0.1	0.15	0.53	0.17	0.08
Total Current Assets	1.66	2.99	7.65	6.17	0.88
Property, Plant & Equipment	8.78	1.74	2	2.29	1.05
Long-Term Investments	2.53	0.84	0.93	1.19	3.36
Other Long-Term Assets	1.53	4.02	3.11	1.96	1.64
Total Long-Term Assets	12.84	6.59	6.04	5.43	6.05
Total Assets	14.49	9.58	13.7	11.61	6.93
Accounts Payable	0.17	0.36	0.39	0.31	0.45
Deferred Revenue	0.08	0.01	0	0	0
Current Debt	1.87	2.26	1.99	2.4	4.34
Other Current Liabilities	3.81	2.91	1.31	2.13	2.02
Total Current Liabilities	5.93	5.54	3.69	4.84	6.81
Long-Term Debt	0.41	0.79	1.12	4.08	0.24
Other Long-Term Liabilities	0.02	0.01	0.01	0.02	0
Total Long-Term Liabilities	0.43	0.8	1.14	4.1	0.24
Total Liabilities	6.36	6.34	4.83	8.94	7.05
Total Debt	2.28	3.05	3.11	6.48	4.58
Debt Growth	-25.43%	-1.83%	-52.00%	41.57%	-
Retained Earnings	-65.42	-54.9	-38.48	-25.64	-15.85
Comprehensive Income	0.52	0.52	0.54	0.56	0.66
Shareholders' Equity	8.39	3.1	8.84	3.44	-0.15
Net Cash / Debt	-1.48	-1.59	3.56	-1.48	-4.42
Net Cash Per Share	-0.34	-0.50	1.42	-0.75	-2.53
Working Capital	-4.28	-2.56	3.96	1.33	-5.94
Book Value Per Share	1.94	0.98	3.53	1.74	-0.09

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).